PharmaCyte Biotech, Inc. (PMCB)
0.4865
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
0.49
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech PE Ratio
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| July 30, 2025 | 0.3835 |
| July 29, 2025 | 0.3817 |
| July 28, 2025 | 0.3817 |
| July 25, 2025 | 0.3573 |
| July 24, 2025 | 0.3555 |
| July 23, 2025 | 0.3592 |
| July 22, 2025 | 0.3702 |
| July 21, 2025 | 0.3723 |
| July 18, 2025 | 0.3854 |
| July 17, 2025 | 0.3817 |
| July 16, 2025 | 0.4191 |
| July 15, 2025 | 0.4137 |
| July 14, 2025 | 0.4116 |
| July 11, 2025 | 0.4041 |
| July 10, 2025 | 0.4103 |
| July 09, 2025 | 0.4153 |
| July 08, 2025 | 0.4116 |
| July 07, 2025 | 0.4116 |
| July 03, 2025 | 0.4153 |
| July 02, 2025 | 0.4266 |
| July 01, 2025 | 0.4266 |
| June 30, 2025 | 0.4079 |
| June 27, 2025 | 0.3854 |
| June 26, 2025 | 0.3929 |
| June 25, 2025 | 0.3854 |
| Date | Value |
|---|---|
| June 24, 2025 | 0.3966 |
| June 23, 2025 | 0.3966 |
| June 20, 2025 | 0.3966 |
| June 18, 2025 | 0.3966 |
| June 17, 2025 | 0.3966 |
| June 16, 2025 | 0.3779 |
| June 13, 2025 | 0.3779 |
| June 12, 2025 | 0.3817 |
| June 11, 2025 | 0.4041 |
| June 10, 2025 | 0.4041 |
| June 09, 2025 | 0.3891 |
| June 06, 2025 | 0.3817 |
| June 05, 2025 | 0.4172 |
| June 04, 2025 | 0.4079 |
| June 03, 2025 | 0.4116 |
| June 02, 2025 | 0.4004 |
| May 30, 2025 | 0.3837 |
| May 29, 2025 | 0.3854 |
| May 28, 2025 | 0.4004 |
| May 27, 2025 | 0.378 |
| May 23, 2025 | 0.3929 |
| May 22, 2025 | 0.3817 |
| May 21, 2025 | 0.3897 |
| May 20, 2025 | 0.3891 |
| May 19, 2025 | 0.3854 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Agenus, Inc. | 3.108 |
| Amgen, Inc. | 27.16 |
| Anika Therapeutics, Inc. | -- |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | -- |
PE Ratio Related Metrics
| Price to Book Value | 0.1569 |
| Price | 0.4865 |
| Earnings Yield | -635.3% |
| Market Cap | 5.223M |